- List
- By Topic
- On Map
- Search Details

"Devic disease"
Need help? See RSS Feeds
Choose a feed type:

"Devic disease" (42 records)
Need help? See Downloading Content for Analysis
For Advanced Users: Full Study Record XML Download
1 | NCT00787722 | Recruiting | Hematopoietic Stem Cell Transplant in Devic's Disease |
|
|
Interventional | Phase 1 Phase 2 |
|
Other |
|
|
40 | All | 16 Years to 65 Years (Child, Adult) | NCT00787722 | DIAD Devic's Disease Auto 2008 | October 2008 | October 2017 | October 2018 | November 7, 2008 | July 21, 2017 |
|
||
2 | NCT00904826 | Completed Has Results |
An Open Label Study of the Effects of Eculizumab in Neuromyelitis Optica |
|
|
Interventional | Phase 1 Phase 2 |
|
Other / Industry |
|
|
14 | All | 18 Years and older (Adult, Senior) | NCT00904826 | 09-001240 | April 2009 | December 2011 | December 2011 | May 20, 2009 | November 4, 2013 | November 4, 2013 |
|
|
3 | NCT02865018 | Completed | Neuromyelitis Optica (NMO) & Cetirizine |
|
|
Interventional | Phase 1 Phase 2 |
|
Other |
|
|
16 | All | 18 Years to 85 Years (Adult, Senior) | NCT02865018 | 13-1513 | April 2014 | February 2016 | February 2016 | August 12, 2016 | August 12, 2016 |
|
||
4 | NCT01759602 | Completed Has Results |
C1-esterase Inhibitor (Cinryze) for Acute Treatment of Neuromyelitis Optica Exacerbation |
|
|
Interventional | Phase 1 |
|
Other / Industry |
|
|
10 | All | 18 Years to 65 Years (Adult) | NCT01759602 | NA_00078437 | January 2013 | November 2013 | November 2013 | January 3, 2013 | July 18, 2014 | July 18, 2014 |
|
|
5 | NCT02087813 | Unknown † | Pilot Study of alpha1-antitrypsin to Treat Neuromyelitis Optica Relapses |
|
|
Interventional | Phase 1 |
|
Other |
|
|
5 | All | 18 Years to 75 Years (Adult, Senior) | NCT02087813 | IRB-27176 | A1AT for NMO | March 2014 | March 2016 | March 14, 2014 | March 14, 2014 |
|
||
6 | NCT01339455 | Terminated | Autologous Hematopoietic Stem Cell Transplant in Neuromyelitis Optica |
|
|
Interventional | Phase 1 Phase 2 |
|
Other |
|
|
3 | All | 18 Years to 65 Years (Adult) | NCT01339455 | CHREB ID# 23282 | SCT-NMO | March 2011 | March 2020 | December 2020 | April 20, 2011 | October 25, 2017 |
|
|
7 | NCT02021825 | Unknown † | Efficacy and Safety of Mitoxantrone in Patients With Refractory Neuromyelitis Optica and Spectrum Disorders |
|
|
Interventional | Phase 4 |
|
Other |
|
|
50 | All | 18 Years to 55 Years (Adult) | NCT02021825 | MITONMO | March 2009 | December 2014 | December 2015 | December 27, 2013 | December 27, 2013 |
|
||
8 | NCT02276963 | Active, not recruiting | Ublituximab for Acute Neuromyelitis Optica (NMO) Relapses |
|
|
Interventional | Phase 1 |
|
Other |
|
|
5 | All | 18 Years to 100 Years (Adult, Senior) | NCT02276963 | IRB00052958 | September 2015 | July 2017 | July 28, 2018 | October 28, 2014 | March 16, 2018 |
|
||
9 | NCT01845584 | Completed | Phase II Clinical Trial of NPB-01 in Patients With Anti-aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorder Not Provided Adequate Effect of Therapy to Steroids Plus Therapy. |
|
|
Interventional | Phase 2 |
|
Industry |
|
|
7 | All | 20 Years and older (Adult, Senior) | NCT01845584 | NPB-01-08/E-01 | May 2013 | August 2015 | August 2015 | May 3, 2013 | April 12, 2017 |
|
||
10 | NCT00501748 | Completed | Safety and Tolerability of Rituximab in Neuromyelitis Optica |
|
|
Interventional | Phase 1 |
|
Other / Industry |
|
|
20 | All | 12 Years to 86 Years (Child, Adult, Senior) | NCT00501748 | H7620-25392-04 | January 2004 | December 2010 | December 2010 | July 16, 2007 | September 27, 2011 |
|
||
11 | NCT02893111 | Active, not recruiting | Efficacy and Safety of Bortezomib as add-on Treatment in Relapsing Neuromyelitis Optica Spectrum Disorder |
|
|
Interventional | Phase 2 |
|
Other |
|
|
5 | Female | 18 Years and older (Adult, Senior) | NCT02893111 | IRB2016-YX-021 | December 2015 | October 2017 | December 2017 | September 8, 2016 | September 8, 2016 |
|
||
12 | NCT02200770 | Recruiting | A Double-masked, Placebo-controlled Study With Open Label Period to Evaluate MEDI-551 in Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders |
|
|
Interventional | Phase 2 Phase 3 |
|
Industry |
|
|
252 | All | 18 Years and older (Adult, Senior) | NCT02200770 | CD-IA-MEDI-551-1155 2014-000253-36 |
January 6, 2015 | November 6, 2019 | November 1, 2023 | July 25, 2014 | April 6, 2018 |
|
||
13 | NCT03350633 | Recruiting | Tocilizumab vs Azathioprine in Neuromyelitis Optica Spectrum Disorders |
|
|
Interventional | Phase 2 Phase 3 |
|
Other |
|
|
118 | All | 18 Years and older (Adult, Senior) | NCT03350633 | IRB2017-YX-009 | TANGO | October 15, 2017 | December 2018 | June 2019 | November 22, 2017 | November 22, 2017 |
|
|
14 | NCT03330418 | Recruiting | A Phase III Study of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Neuromyelitis Optica Spectrum Disorders |
|
|
Interventional | Phase 3 |
|
Industry |
|
|
118 | All | 18 Years to 65 Years (Adult) | NCT03330418 | C009NMOSDCLLI | September 21, 2017 | December 2020 | June 2021 | November 6, 2017 | November 7, 2017 |
|
||
15 | NCT02850705 | Recruiting | The French Cohort and Biobank of Devic's Neuromyelitis Optica and Related Neurological Disorders (NMOSD) (NOMADMUS) |
|
Observational |
|
Other |
|
|
650 | All | Child, Adult, Senior | NCT02850705 | D50742 | NOMADMUS | January 2010 | January 2019 | January 2019 | August 1, 2016 | January 12, 2018 |
|
|||
16 | NCT01364246 | Unknown † | Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Therapy for Patients With Progressive Multiple Sclerosis and Neuromyelitis Optica |
|
|
Interventional | Phase 1 Phase 2 |
|
Industry / Other |
|
|
20 | All | 18 Years to 60 Years (Adult) | NCT01364246 | BKCR-MS-1.0(2010) | January 2010 | March 2013 | December 2014 | June 2, 2011 | November 28, 2012 |
|
||
17 | NCT02003144 | Enrolling by invitation | An Open Label Extension Trial of Eculizumab in Relapsing NMO Patients |
|
|
Interventional | Phase 3 |
|
Industry |
|
|
132 | All | 18 Years and older (Adult, Senior) | NCT02003144 | ECU-NMO-302 2013-001151-12 |
January 2015 | December 2018 | December 2018 | December 6, 2013 | March 8, 2018 |
|
||
18 | NCT01892345 | Active, not recruiting | A Double Blind Trial To Evaluate The Safety And Efficacy Of Eculizumab In Relapsing NMO Patients (PREVENT Study) |
|
|
Interventional | Phase 3 |
|
Industry |
|
|
132 | All | 18 Years and older (Adult, Senior) | NCT01892345 | ECU-NMO-301 | January 2014 | May 2018 | May 2018 | July 4, 2013 | March 7, 2018 |
|
||
19 | NCT03452176 | Recruiting | Scrambler Trial for Pain in NMOSD |
|
|
Interventional | Phase 2 |
|
Other |
|
|
22 | All | 18 Years and older (Adult, Senior) | NCT03452176 | IRB00115699 | February 21, 2018 | June 30, 2019 | September 30, 2019 | March 2, 2018 | April 6, 2018 |
|
||
20 | NCT02249676 | Unknown † | Autologous Mesenchymal Stem Cells for the Treatment of Neuromyelitis Optica Spectrum Disorders |
|
|
Interventional | Phase 2 |
|
Other |
|
|
15 | All | 18 Years to 80 Years (Adult, Senior) | NCT02249676 | IRB2013-055-02 | January 2013 | December 2014 | December 2014 | September 25, 2014 | September 25, 2014 |
|
||
21 | NCT03062579 | Active, not recruiting | A Longitudinal Study of ACTEMRA® (Tocilizumab) as Monotherapy in Highly Active NMOSD |
|
|
Interventional | Phase 1 Phase 2 |
|
Other |
|
|
10 | All | 18 Years and older (Adult, Senior) | NCT03062579 | IRB2017-YX-006 | December 1, 2016 | January 1, 2018 | April 1, 2018 | February 23, 2017 | February 23, 2017 |
|
||
22 | NCT03002038 | Completed | Comparison of Clinical Effects of Azathioprine and Rituximab NMO-SD Patients |
|
|
Interventional | Phase 2 Phase 3 |
|
Other |
|
|
76 | All | 18 Years to 50 Years (Adult) | NCT03002038 | 395275 | September 2015 | November 2016 | December 2016 | December 23, 2016 | January 2, 2017 |
|
||
23 | NCT02836327 | Recruiting | Multimodel Magnetic Resonance Imaging (MRI)of Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders |
|
|
Observational |
|
Other |
|
|
300 | All | 18 Years to 60 Years (Adult) | NCT02836327 | MS and NMOSD-ChinaPLAGH | September 2014 | September 2019 | September 2021 | July 19, 2016 | August 9, 2016 |
|
|||
24 | NCT01777412 | Completed Has Results |
Efficacy of Bevacizumab (Avastin) in Treatment of Acute NMO Exacerbations |
|
|
Interventional | Phase 1 |
|
Other / Industry |
|
|
10 | All | 18 Years to 70 Years (Adult, Senior) | NCT01777412 | Avastin_NMO_1 | June 2013 | February 2015 | May 2015 | January 28, 2013 | August 21, 2015 | May 29, 2015 |
|
|
25 | NCT01500681 | Active, not recruiting | Maintenance Plasma Exchange for Neuromyelitis Optica |
|
|
Observational |
|
Other / Industry |
|
|
14 | All | 18 Years and older (Adult, Senior) | NCT01500681 | 10-007339 MultiPLEX-2012 |
MultiPLEX | June 2012 | August 2017 | December 28, 2011 | March 22, 2017 |
|
|||
26 | NCT01024985 | Unknown † | Evaluation of Neural Loss in Multiple Sclerosis and Neuromyelitis Optica Using High Resolution Oct |
|
Observational |
|
Other |
|
40 | All | 15 Years to 60 Years (Child, Adult) | NCT01024985 | 0190/09 | September 2009 | December 2010 | December 2011 | December 3, 2009 | June 28, 2010 |
|
|||||
27 | NCT02028884 | Recruiting | Efficacy and Safety Study as Add-on Therapy of SA237 to Treat NMO and NMOSD |
|
|
Interventional | Phase 3 |
|
Industry |
|
|
70 | All | 12 Years to 74 Years (Child, Adult, Senior) | NCT02028884 | SA-307JG 2013-003752-21 |
February 2014 | July 2018 | June 2020 | January 7, 2014 | March 12, 2018 |
|
||
28 | NCT02809079 | Enrolling by invitation | Mycophenolate Mofetil Treatment With Neuromyelitis Optica Spectrum Disorders in Chinese Patients |
|
|
Interventional | Phase 4 |
|
Other |
|
|
100 | All | 18 Years to 65 Years (Adult) | NCT02809079 | 2016017 | MONICA | January 2016 | December 2017 | December 2017 | June 22, 2016 | June 22, 2016 | ||
29 | NCT02073279 | Active, not recruiting | Efficacy and Safety Study as Monotherapy of SA237 to Treat NMO and NMOSD |
|
|
Interventional | Phase 3 |
|
Industry |
|
|
95 | All | 18 Years to 74 Years (Adult, Senior) | NCT02073279 | SA-309JG | August 2014 | October 2018 | March 2019 | February 27, 2014 | October 31, 2017 |
|
||
30 | NCT00304291 | Completed | A Pilot Study of Mitoxantrone for the Treatment of Recurrent Neuromyelitis Optica (Devic’s Disease) |
|
|
Interventional | Phase 4 |
|
Other / Industry |
|
|
5 | All | 18 Years to 55 Years (Adult) | NCT00304291 | JNI-NMO-101 | August 2001 | May 2004 | March 17, 2006 | November 28, 2006 |
|
|||
31 | NCT02283671 | Recruiting | Treatment of Multiple Sclerosis and Neuromyelitis Optica With Regulatory Dendritic Cell: Clinical Trial Phase 1 B |
|
|
Interventional | Phase 1 |
|
Other |
|
|
22 | All | 18 Years to 65 Years (Adult) | NCT02283671 | TolDec-EM-NMO | September 2015 | December 2018 | December 2018 | November 5, 2014 | November 7, 2017 |
|
||
32 | NCT02398994 | Terminated | A Multicentre randomiSed Controlled TRial of IntraVEnous Immunoglobulin Versus Standard Therapy for Transverse Myelitis |
|
|
Interventional | Phase 3 |
|
Other |
|
|
2 | All | 1 Year and older (Child, Adult, Senior) | NCT02398994 | RJ115/N065 2014-002335-34 11/129/148 12127581 |
STRIVE | March 2015 | March 2016 | March 2016 | March 26, 2015 | July 20, 2016 |
|
|
33 | NCT02889965 | Recruiting | The French Multiple Sclerosis Registry |
|
Observational |
|
Other |
|
|
54000 | All | up to 100 Years (Child, Adult, Senior) | NCT02889965 | 69HCL14_0385 | OFSEP | January 2011 | December 2019 | December 2019 | September 7, 2016 | September 7, 2016 |
|
|||
34 | NCT03370965 | Not yet recruiting | Optic Neuritis Differential Diagnosis Study |
|
|
Interventional | Not Applicable |
|
Other |
|
|
150 | All | 18 Years and older (Adult, Senior) | NCT03370965 | 17/B/01 | ONDDS | January 2018 | January 2023 | October 2023 | December 13, 2017 | December 13, 2017 | ||
35 | NCT01623076 | Recruiting | The Longitudinal CONQUER Study of Rare Neuroimmunologic Disorders |
|
Observational |
|
Other |
|
|
150 | All | 6 Years and older (Child, Adult, Senior) | NCT01623076 | STU-022012-084 | June 2012 | June 2020 | June 2022 | June 19, 2012 | January 3, 2018 |
|
||||
36 | NCT02166346 | Completed Has Results |
Safety and Efficacy of Sustained Release Dalfampridine in Transverse Myelitis (Re-Launch) |
|
|
Interventional | Phase 2 |
|
Other / Industry |
|
|
24 | All | 18 Years to 70 Years (Adult, Senior) | NCT02166346 | NA_00090799 | February 2014 | January 8, 2017 | January 8, 2017 | June 18, 2014 | April 17, 2018 | April 17, 2018 |
|
|
37 | NCT03138421 | Recruiting | Central Pain Study for ABX-1431 |
|
|
Interventional | Phase 1 |
|
Industry |
|
|
32 | All | 18 Years and older (Adult, Senior) | NCT03138421 | ABX-1431_PN009 | August 1, 2017 | February 2018 | February 2018 | May 3, 2017 | August 4, 2017 |
|
||
38 | NCT00445367 | Active, not recruiting | Biobank For MS And Other Demyelinating Diseases |
|
Observational |
|
Other |
|
3226 | All | Child, Adult, Senior | NCT00445367 | ACP-001 | May 2006 | October 2026 | March 9, 2007 | January 17, 2018 |
|
||||||
39 | NCT00004645 | Unknown † | Phase III Randomized, Double-Blind, Sham-Controlled Study of Plasma Exchange for Acute Severe Attacks of Inflammatory Demyelinating Disease Refractory to Intravenous Methylprednisolone |
|
|
Interventional | Phase 3 |
|
NIH / Other |
|
22 | All | 18 Years to 60 Years (Adult) | NCT00004645 | 199/11693 MAYOC-29493 |
January 1995 | February 25, 2000 | June 24, 2005 | ||||||
40 | NCT03121105 | Active, not recruiting | Pathologic-MRI Findings in Atypical IIDD |
|
Observational |
|
Other |
|
|
25 | All | 18 Years and older (Adult, Senior) | NCT03121105 | RECHMPL17_0078 | IIDD | January 1, 2017 | December 1, 2017 | December 31, 2017 | April 19, 2017 | November 27, 2017 | ||||
41 | NCT03011541 | Recruiting | Stem Cell Ophthalmology Treatment Study II |
|
|
Interventional | Not Applicable |
|
Industry |
|
|
500 | All | 18 Years and older (Adult, Senior) | NCT03011541 | SCOTS2 | SCOTS2 | January 2016 | January 2020 | January 2021 | January 5, 2017 | February 5, 2018 |
|
|
42 | NCT01920867 | Enrolling by invitation | Stem Cell Ophthalmology Treatment Study |
|
|
Interventional | Not Applicable |
|
Industry |
|
|
300 | All | 18 Years and older (Adult, Senior) | NCT01920867 | ICMS-2013-0019. | SCOTS | August 2013 | August 2018 | August 2019 | August 12, 2013 | January 18, 2018 |
|
† Study has passed its completion date and status has not been verified in more than two years.